ArticleFrontiers in oncology2025
Prognostic significance of peripheral blood inflammatory biomarkers (SII, PLR, NLR, LMR, SIRI, PIV, PNI) in lip cancer: NLR as an independent biomarker for survival outcomes.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of NLR versus PLR and LMR in patients with oral squamous cell carcinoma: a meta-analysis.BMC oral health · 2026Pooled it
- Prognostic significance of inflammation-based markers in nasopharyngeal carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.Journal of clinical medicine · 2026Article
- Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors.Journal of clinical medicine · 2026Article
- Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018.Translational cancer research · 2026Article
- CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol.BMC cancer · 2026Article
- The microbiome-inflammation-immune axis in oral squamous cell carcinoma: from mechanistic insights to therapeutic perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lip cancer is a type of oral cancer with a different prognosis than that of other cancers. However, a lack of well-established understanding of the relationship between the peripheral blood inflammatory biomarker (PBIB) and prognosis in patients with lip cancer is evident. This study investigated the prognostic value of inflammatory markers and other unfavourable prognostic factors. It compares the systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV) and prognosis nutritional index (PNI) in patients with lip cancer. Materials and methods: This retrospective study included 122 patients with lip cancer. Clinical characteristics and hematological parameters were retrospectively obtained prior to treatment. SII, PLR, NLR, LMR, SIRI, PIV and PNI were calculated to analyze their effects on survival and recurrence further. Results: Receiver operating characteristics curve analysis demonstrated SII >534.286, PLR >146.528, NLR >2.134, LMR ≤4.000, SIRI >0.7100, PIV >211.930, PNI ≤51.900 were factors associated with increased mortality. Univariate analysis showed that these inflammatory parameters were associated with a lower survival rate. In multivariate analysis, NLR was identified as having a cumulative role in predicting overall survival (HR=5.885, 95% CI: 2.131-16.256, Conclusion: This study revealed that NLR is a promising blood biomarker in patients with lip cancer. The predictive power of other PBIBs, albeit showing a trend towards significance, were not statistically significant, possibly due to the limited number of cases. The clinical applicability of other hematological indicators requires further study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.